TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00586534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I/GDC + VR/CER
Description: NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I/GDC
Description: NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
Study: NCT00332852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg/day - oraly
Study: NCT01819857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xomolix 0.625 mg intravenously
Description: intravenous administration of 0.625 mg droperidol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xomolix 1.25 mg
Description: intravenous administration of 1.25 mg droperidol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran 8 mg
Description: intravenous administration of 8 mg ondansetron
Study: NCT03489811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Essential Oil Blend
Description: The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
Study: NCT04582695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder
Description: Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder. Sessions will be 60 minutes in length. It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes. In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Exposure Therapy
Description: Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
Study: NCT03514394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The clinic's usual care includes counseling, substance use disorder treatment, peer support services, and some elements of traditional BA (not the modified BA).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Activation (Task Sharing)
Description: This intervention will include all core elements of Behavioral Activation (BA), which is a behavioral intervention that identifies work, social, health, or family activities that patients have stopped engaging in because of their mood. The intervention will also include a Task Sharing modification, which will allow clinicians and care managers to more efficiently share the tasks involved in BA.
Study: NCT04307264

Intervention type: PROCEDURE
Intervention: Esophagogasrtoduodendoscopy, liver stiffness measurement
Description: Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.
Study: NCT01353911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2b
Description: 1.5 μg/kg/week subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.
Study: NCT04348825

Intervention type: DEVICE
Intervention: Electroconvulsive therapy
Study: NCT04052906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Planned Inhaler Medication Trainning
Study: NCT01353911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.
Study: NCT03550508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-RANKL Monoclonal Antibody
Description: JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
Study: NCT01372020

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: neuromuscular electrical stimulation
Description: The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation
Description: The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
Study: NCT01619631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Tai Chi intervention
Description: Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education control group
Description: The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
Study: NCT01006798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: enteric coated capsule containing no vaccine virus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: enteric coated capsule containing no vaccine virus
Study: NCT01353911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.
Study: NCT04174287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-AV45
Description: The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
Study: NCT01353911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 300 mg to 700 mg orally twice daily.
Study: NCT02895945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)
Description: In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
Study: NCT01006798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: enteric coated capsule containing no vaccine virus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: enteric coated capsule containing no vaccine virus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: enteric coated capsule containing no vaccine virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn
Description: a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn
Description: a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn
Description: a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn
Description: a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn
Description: a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi Pasteur Influenza Virus Vaccine, H5N1
Description: Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi Pasteur Influenza Virus Vaccine, H5N1
Description: Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi Pasteur Influenza Virus Vaccine, H5N1
Description: Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi Pasteur Influenza Virus Vaccine, H5N1
Description: Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi Pasteur Influenza Virus Vaccine, H5N1
Description: Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
Study: NCT03849157

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor reconstructive surgery
Description: transvaginal mesh implantation for pelvic organ prolapse

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor reconstructive surgery
Description: transvaginal mesh implantation for pelvic organ prolapse
Study: NCT03632915

Intervention type: DRUG
Intervention: Levetiracetam
Description: Standard of care

Intervention type: DRUG
Intervention: Lacosamide
Description: Standard of care

Intervention type: DRUG
Intervention: Phenytoin
Description: Standard of care
Study: NCT02706587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: No electrostimulation
Study: NCT00479479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)
Description: an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
Study: NCT03481140

Intervention type: DEVICE
Intervention: TissuGlu Surgical Adhesive
Description: lysine-derived urethane adhesive
Study: NCT03730415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Viscoelastic (VE) Guided Transfusion
Description: A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
Study: NCT03437824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin
Description: 1,000 mg, Once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride, Once
Study: NCT02219503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/Paritaprevir/Ritonavir
Description: Tablet; paritaprevir co-formulated with ritonavir and ombitasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Tablet
Study: NCT02580357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Low Level Laser Therapy on the palatal donor site of connective tissue graft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Low Level Laser Therapy on the palatal donor site of connective tissue graft.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Low Level Laser Therapy on the palatal donor site of connective tissue graft.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GaAlAs laser
Description: Utilization of GaAlAs laser to irradiation on the palatal donor site.
Study: NCT04420156

Intervention type: OTHER
Intervention: No intervention administered.
Description: Eye exams are standard of care and would be performed regardless of participation in this study.
Study: NCT04238351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transnasal humidified rapid insufflation ventilator exchange
Description: applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional face mask
Description: applying oxygen using usual face mask
Study: NCT03770650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting
Description: DK crush technique with SYNERGY (Boston Scientific) drug-eluting stent implantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stenting
Description: DK crush technique with SYNERGY (Boston Scientific) drug-eluting stent implantation.
Study: NCT01272830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules taken twice daily with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatone®B
Description: Two capsules taken twice daily with meals
Study: NCT01336075

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous radiofrequency catheter ablation
Description: Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini invasive thoracoscopic radiofrequency ablation
Description: Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
Study: NCT02478242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nafamostat mesilate
Description: nafamostat mesilate use for anticoagulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT05442944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic procedures
Description: As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
Study: NCT03171987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch local application
Description: Attach the patch to back pain area 1 piece per day with no more than 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen patch local application
Description: Attach the patch to back pain area 1 piece per day with no more than 6 hours.
Study: NCT04839159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at the age of 6 and 12 months, 2-3-4 years
Study: NCT05240872

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection
Description: Plantar fascia injection therapy with PRP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ABI injection
Description: ABI injection
Study: NCT00976521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab local infusion
Description: Local infusion of abciximab using the ClearWay™ RX Infusion Catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab local infusion
Description: Local infusion of abciximab using the ClearWay™ RX Infusion Catheter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No local infusion
Description: Intervention without local infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No local infusion
Description: Intervention without local infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Description: Thrombus aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombus aspiration
Description: Thrombus aspiration
Study: NCT01306682

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine
Description: 0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.5ml normal saline administered into deltoid muscle of non dominant arm
Study: NCT05756062

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)
Description: Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
Study: NCT02155166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracervical anesthesia with lidocaine 2%
Description: 5 min before LNG-IUS placemen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 400 mg
Description: 1 hour prior to the LNG-IUS insertion
Study: NCT01712529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise
Description: Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
Study: NCT01159665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: 125µg ocriplasmin intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: 125µg ocriplasmin intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: 125µg ocriplasmin intravitreal injection
Study: NCT03489811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Essential Oil Blend
Description: The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Blend
Description: The control blend consists of inert vegetable oils which are produced from plant matter.
Study: NCT02224755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAS
Description: Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate II LVAS
Description: Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure